Single Source: Coordinating Center (CC) for the Small Cell Lung Cancer (SCLC) Consortium (U24 Clinical Trial Not Allowed)

Forecasted opportunity (not yet open for applications; expected to be posted around 2026-11-25; estimated application due date 2027-01-25). Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to continue to support the Coordinating Center (CC) for the Small Cell Lung Cancer (SCLC) Consortium, which coordinates research on prevention, diagnosis, treatment, and mechanisms of resistance in SCLC. The CC manages administrative activities, centralized databases, tissue banking and a virtual biospecimen resource, biostatistics and bioinformatics support, in vivo and in vitro model repositories, and communications and website operations for the Consortium. Since its establishment in response to the Recalcitrant Cancer Research Act, the Consortium has catalyzed SCLC-focused research and enabled major advances in molecular characterization, tumor heterogeneity, microenvironment and immune evasion, biomarker development, preclinical models, therapeutic strategies, and clinical translation. The current U24 CC, based at Sloan Kettering with collaborating institutions, organizes meetings, maintains extensive -omics and model resources, supports young investigators, and provides datasets and models to the research community. The reissue NOFO will support a five-year cooperative agreement to sustain these shared resources and collaborations. This is a Forecast for a single source that will invite application(s) from eligible organization(s) to apply. Please see the Eligibility Section for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered for funding.